Invokana Lawsuits Alleging Kidney Failure Filed
Filed in: Invokana
References
- Cefalu, William T., and Matthew C. Riddle. "SGLT2 Inhibitors: The Latest “New Kids on the Block”!" Diabetes Care. American Diabetes Association, Mar. 2015. Web. 17 May 2016. http://care.diabetesjournals.org/content/38/3/352.
- "FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density." FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density. U.S. Food and Drug Administration, 10 Sept. 2015. Web. 17 May 2016. http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm.
- DKA (Ketoacidosis) & Ketones. (2013, August 21). Retrieved May 18, 2016, from http://www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html?referrer=https%3A%2F%2Fwww.google.com%2F
- U.S. Food and Drug Administration. (2015, May 15). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
- "Medication Guide INVOKANA® (in-vo-KAHN-uh) (canagliflozin) Tablets." (n.d.): n. pag. Www.fda.gov. U.S. Food and Drug Administration. Web. 17 May 2016. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM346637.pdf
- "U.S. Food and Drug Administration." FDA Approves Invokana to Treat Type 2 Diabetes. U.S. Food and Drug Administration, 29 Mar. 2013. Web. 17 May 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm